These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37998841)

  • 21. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
    Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the Use of Dalbavancin for Off-Label Indications.
    Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
    Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term Dalbavancin for Suppression of Gram-Positive Chronic Left Ventricular Assist Device Infections.
    Rowe S; Green S; Albrecht B; Pouch SM
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad537. PubMed ID: 38023541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years.
    Salinas-Botrán A; Olmos-Blanco C; Fernández de Velasco-Pérez D; Guzmán-Carreras A; Morales-Rosas A; Gómez-Ramírez D
    Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; ():. PubMed ID: 38763866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.
    Morata L; Cobo J; Fernández-Sampedro M; Guisado Vasco P; Ruano E; Lora-Tamayo J; Sánchez Somolinos M; González Ruano P; Rico Nieto A; Arnaiz A; Estébanez Muñoz M; Jiménez-Mejías ME; Lozano Serrano AB; Múñez E; Rodriguez-Pardo D; Argelich R; Arroyo A; Barbero JM; Cuadra F; Del Arco A; Del Toro MD; Guio L; Jimenez-Beatty D; Lois N; Martin O; Martínez Alvarez RM; Martinez-Marcos FJ; Porras L; Ramírez M; Vergas García J; Soriano A
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections.
    Cattaneo D; Fusi M; Galli L; Genovese C; Giorgi R; Matone M; Merli S; Colaneri M; Gori A
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0002324. PubMed ID: 38385700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection.
    Lange A; Thunberg U; Söderquist B
    BMC Infect Dis; 2023 Oct; 23(1):706. PubMed ID: 37858087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Dalbavancin.
    Chiriac U; Rau H; Frey OR; Röhr AC; Klein S; Meyer AL; Morath B
    Antibiotics (Basel); 2022 Apr; 11(5):. PubMed ID: 35625185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Off-label use of dalbavancin in children: a case series.
    Gamell A; Velasco-Arnaiz E; López-Ramos MG; Ríos-Barnés M; Simó-Nebot S; Fumadó V; Noguera-Julián A; Fortuny C
    J Antimicrob Chemother; 2024 Jul; ():. PubMed ID: 38958260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
    Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
    Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
    Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
    J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immediate and long-term results of valve replacement for native and prosthetic valve endocarditis.
    Delay D; Pellerin M; Carrier M; Marchand R; Auger P; Perrault LP; Hébert Y; Cartier R; Pagé P; Pelletier LC
    Ann Thorac Surg; 2000 Oct; 70(4):1219-23. PubMed ID: 11081874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
    Dimopoulou D; Mantadakis E; Koutserimpas C; Samonis G
    Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.
    Kussmann M; Obermueller M; Berndl F; Reischer V; Veletzky L; Burgmann H; Poeppl W
    Sci Rep; 2018 Jun; 8(1):9661. PubMed ID: 29941909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
    Evins C; Lancaster H; Schnee AE
    Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.